Cutaneous presentation of posttransplant lymphoproliferative disorder

Schumann, Keith; Oriba, Howard A.; Bergfeld, Wilma F.; Hsi, Eric D.; Hollandsworth, Kimberly

doi:10.1016/s0190-9622(00)90273-1

Cited by 36 publications

(32 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cutaneous PTLD behaves less aggressively than identical extracutaneous lesions. 3,[7][8][9][10][11] PTLD can also be classified by pathology. The morphologic categories of PTLD include plasmacytic hyperplasia/infectious mononucleosis-like PTLD, polymorphic PTLD, monomorphic B-cell PTLD, monomorphic T-cell PTLD, and Hodgkin lymphoma/Hodgkin lymphoma-like PTLD.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Localized cutaneous posttransplant Epstein-Barr virus–associated lymphoproliferative disorder

Capaldi¹,

Robinson‐Bostom²,

Kerr³

et al. 2004

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Previously reported cases have been treated by reduction of immunosuppression, surgery, or radiotherapy, with good clinical outcomes. 3,[7][8][9][10][11] Our patient responded completely to a reduction of immunosuppression with no evidence of recurrence or metastasis 2 years later. …”

Section: Discussionmentioning

confidence: 99%

Localized cutaneous posttransplant Epstein-Barr virus–associated lymphoproliferative disorder

Capaldi¹,

Robinson‐Bostom²,

Kerr³

et al. 2004

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…Clinical features including initial disease for transplant, time to PTLD, site of PTLD, stage of the patient, recurrence, immunosuppression regimen, and type and response to treatment, were evaluated for all PTLDs. One LTx patient (Patient 3) was previously reported (25). Autopsies were performed in five cases (1 LTx patient and 4 non-LTx patients).…”

Section: Methodsmentioning

confidence: 99%

Posttransplant Lymphoproliferative Disorders in Lung Transplant Patients: The Cleveland Clinic Experience

et al. 2002

View full text Add to dashboard Cite

PTLD is a well-recognized complication of organ transplantation. Large series of heart, renal, and liver transplants have been examined for the incidence and behavior of PTLD. However, reports of the incidence and characteristics of PTLDs in lung transplant (LTx) patients are few. We report our experience with PTLDs in a large series of LTx recipients at a single institution and compare them to other solid organ transplant recipient PTLDs seen at our institution. Twenty-eight patients were found to have PTLD, of whom 8 were lung transplant recipients. We evaluated nine PTLD specimens from these 8 patients for their histology, immunophenotype (CD20, CD3, EBV-LMP1), EBER status by in situ hybridization, and clinical features. The incidence of PTLD was 3.3% (8/244 patients). The time to development of PTLD, after transplant, was short (median time, 7 mo). All were of B-cell lineage. Overall, EBV was demonstrated in 77.7% (7 of 9 specimens) of PTLDs. All specimens tested for clonality were found to be monoclonal. Five patients died, with a median time to death of only 4.6 months. PTLDs in LTx patients are EBV-associated B-cell, predominantly monoclonal lymphoid lesions similar to other solid organ transplant PTLDs. Compared with other solid organ transplant recipients with PTLD at our institution, PTLDs in LTx patients have a propensity to involve the transplanted organ (P ‫؍‬ .001, Fisher's exact test), occur earlier after transplant (P ‫؍‬ .003, Wilcoxon test), and have a shorter survival (P ‫؍‬ .002, log rank test). Reasons for this may include the relatively higher level of immunosuppression required in these patients and limited options in decreasing it. Although the incidence is low, careful early monitoring of lung transplantation patients is warranted because of the poor prognosis of patients developing this complication.

show abstract

“…When they do occur, skin lesions of PTLD present as solitary or multiple nontender erythematous nodules, exophytic tumors, ulcers, indurated plaques, or maculopapules, with reported areas of involvement including the forehead, lower lip, upper and lower extremities, and trunk. [16][17][18][19][20][21][22][23][24][25][26][27][28] Finally, an angiocentric and angioinvasive lymphocytic infiltrate has, to our knowledge, been associated only once with PTLD, in a case that also showed features of LYG. 29 Our patient also presented with features suggestive of LYG, including lesions in the skin and lungs and an EBV-positive angiocentric and angioinvasive lymphocytic infiltrate.…”

Section: Discussionmentioning

confidence: 99%

Posttransplantation lymphoproliferative disease with features of lymphomatoid granulomatosis in a lung transplant patient

Kwon

Katz²,

Seykora³

et al. 2006

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Cutaneous presentation of posttransplant lymphoproliferative disorder

Cited by 36 publications

References 17 publications

Localized cutaneous posttransplant Epstein-Barr virus–associated lymphoproliferative disorder

Localized cutaneous posttransplant Epstein-Barr virus–associated lymphoproliferative disorder

Posttransplant Lymphoproliferative Disorders in Lung Transplant Patients: The Cleveland Clinic Experience

Posttransplantation lymphoproliferative disease with features of lymphomatoid granulomatosis in a lung transplant patient

Contact Info

Product

Resources

About